• Explore /
  • Poster
  • / Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer.

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.

Abstract Poster

Authors

Josep Tabernero

Josep Tabernero

Vall d’Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain

Josep Tabernero , Axel Grothey , Dirk Arnold , Michel Ducreux , Peter J. O'Dwyer , Maurizio Perdicchio , Alexander Abbas , Meghna Das Thakur , Natsumi Irahara , Anila Tahiri , Hans-Joachim Schmoll , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02291289

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3570)

DOI

10.1200/JCO.2021.39.15_suppl.3570

Abstract #

3570

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Rita Migliorino

First Author: Brian I. Rini

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.

Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.

First Author: Akihito Kawazoe

First Author: Yoo Na Kim